|  | Eroin Yoksunluk |  | 
|  08-20-2012 | #1 | 
| 
Prof. Dr. Sinsi
 |   Eroin YoksunlukYoksunluk Black tar heroin The withdrawal syndrome from heroin may begin starting from within 6 to 24 hours of discontinuation of sustained use of the drug; however, this time frame can fluctuate with the degree of tolerance as well as the amount of the last consumed dose  Symptoms may include: sweating, malaise, anxiety, depression, persistent and intense penile erection in males (priapism), extra sensitivity of the genitals in females, general feeling of heaviness, cramp-like pains in the limbs, yawning and lacrimation, sleep difficulties, cold sweats, chills, severe muscle and bone aches not precipitated by any physical trauma; nausea and vomiting, diarrhea, goose bumps, cramps, and fever  In an addict with a high tolerance, heroin withdrawal may even lead to death, although debate amongst professionals continues about the likelihood of death being an end result of simple withdrawal  [10]  [11]  Many addicts also complain of a painful condition, the so-called "itchy blood", which often results in compulsive scratching that causes bruises and sometimes ruptures the skin, leaving scabs  Abrupt termination of heroin use causes muscle spasms in the legs of the user (restless leg syndrome)  Users taking the "cold turkey" approach (withdrawal without using symptom-reducing or counteractive drugs) are more likely to experience the negative effects of withdrawal in a more pronounced manner  Two general approaches are available to ease the physical part of opioid withdrawal  The first is to substitute a longer-acting opioid such as methadone or buprenorphine for heroin or another short-acting opioid and then slowly taper the dose  In the second approach, benzodiazepines such as diazepam (Valium) may temporarily ease the often extreme anxiety of opioid withdrawal  The most common benzodiazepine employed as part of the detox protocol in these situations is oxazepam (Serax)  Benzodiazepine use must be prescribed with care because benzodiazepines have a great addiction potential, and many opioid addicts also use other central nervous system depressants including barbiturates  Also, though unpleasant, opioid withdrawal seldom has the potential to be fatal, whereas complications related to withdrawal from benzodiazepines, barbiturates and alcohol (such as epileptic seizures, cardiac arrest, and delirium tremens) can prove hazardous and are potentially fatal  Many symptoms of opioid withdrawal are due to rebound hyperactivity of the sympathetic nervous system, which can be suppressed with clonidine (Catapres), a centrally-acting alpha-2 agonist primarily used to treat hypertension  Buprenorphine is one of the substances most recently licensed for the substitution of illegal opioids  Being a partial opioid agonist/antagonist, it develops a lower grade of tolerance than heroin or methadone due to the so-called ceiling effect  It also has less severe withdrawal symptoms than heroin when discontinued abruptly, which should never be done without proper medical supervision  It is usually administered every 24-48 hrs  Buprenorphine is a kappa-opioid receptor antagonist  This gives the drug an anti-depressant effect, increasing physical and intellectual activity  Buprenorphine also acts as a partial agonist at the same μ-receptor where illicit opioids like heroin exhibit their action  Due to its effects on this receptor, all patients whose tolerance is above a certain level are unable to obtain any "high" from other opioids during buprenorphine treatment except for very high doses  Researchers at Johns Hopkins University have been testing a sustained-release "depot" form of buprenorphine that can relieve cravings and withdrawal symptoms for up to six weeks  [12] A sustained-release formulation would allow for easier administration and adherence to treatment, and reduce the risk of diversion or misuse  Methadone is another μ-opioid agonist most often used to substitute for heroin in treatment for heroin addiction  Compared to heroin, methadone is well (but slowly) absorbed by the gastrointestinal tract and has a much longer duration of action of approximately 24 hours  Thus methadone maintenance avoids the rapid cycling between intoxication and withdrawal associated with heroin addiction  In this way, methadone has shown some success as a "less harmful substitute"; despite bearing about the same addiction potential as heroin, it is recommended for those who have repeatedly failed to complete withdrawal or have recently relapsed  As of 2005, the μ-opioid agonist buprenorphine is also being used to manage heroin addiction, being a superior, though still imperfect and not yet widely known alternative to methadone  Methadone, since it is longer-acting, produces withdrawal symptoms that appear later than with heroin, but usually last considerably longer and can in some cases be more intense  Methadone withdrawal symptoms can potentially persist for over a month, compared to heroin where significant physical symptoms would subside in 4 days  Two opioid antagonists are known: naloxone and the longer-acting naltrexone  These two medications block the effects of heroin, as well as the other opioids at the receptor site  Recent studies have suggested that the addition of naloxone and naltrexone may improve the success rate in treatment programs when combined with the traditional therapy   The University of Chicago undertook preliminary development of a heroin vaccine in monkeys during the 1970s, but it was abandoned  There were two main reasons for this  Firstly, when immunised monkeys had an increase in dose of x16, their antibodies became saturated and the monkey had the same effect from heroin as non-immunised monkeys  Secondly, until they reached the x16 point immunised monkeys would substitute other drugs to get a heroin-like effect  These factors suggested that immunised human addicts would simply either take massive quantities of heroin, or switch to other hard drugs, which is known as cross-tolerance  There is also a controversial treatment for heroin addiction based on a plant-derived African drug, ibogaine  Many people travel abroad for ibogaine treatments that generally interrupt substance use disorders for 3 - 6 months or more in up to 80% of patients  Relapse often occurs when the person returns home to their normal environment however, where drug seeking behaviour may return in response to social and environmental cues  Ibogaine treatments are carried out in several countries including Mexico and Canada as well as, in South and Central America and Europe  Opioid withdrawal therapy is the most common use of ibogaine  Some patients find ibogaine therapy more effective when it is given several times over the course of a few months or years  A synthetic derivative of ibogaine, 18-methoxycoronaridine was specifically designed to overcome cardiac and neurotoxic effects seen in some ibogaine research but, the drug has not yet found its way into clinical research   Kaynak : Wikipedia | 
|   | 
|  | 
| Konu Araçları | Bu Konuda Ara | 
| Görünüm Modları | |
|  |